Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotechnology company Emergent BioSolutions
So what: After yesterday's close, Emergent posted a fourth-quarter profit of $26.2 million, or $0.76 per share, versus the average analyst estimate of just $0.68 per share. Curiously enough, the stock opened Friday down 16%, only to spike quickly back up. At the time of publication, Emergent shares are off only about 2% on more than triple the average volume.
Now what: I wouldn't read too much into today's wacky trading. Fundamentally, sales of Emergent's anthrax treatment BioThrax are booming, with management forecasting solid full-year earnings of $35 million to $45 million on a top line of $320 million to $340 million -- largely in line with analyst estimates. Wild, seemingly nonsensical price swings just come with the small-cap biotech territory, and investors would do well to keep this one in proper perspective.
Interested in more info on Emergent? Add it to your watchlist.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.